[go: up one dir, main page]

WO2008070358A3 - Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci - Google Patents

Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci Download PDF

Info

Publication number
WO2008070358A3
WO2008070358A3 PCT/US2007/083034 US2007083034W WO2008070358A3 WO 2008070358 A3 WO2008070358 A3 WO 2008070358A3 US 2007083034 W US2007083034 W US 2007083034W WO 2008070358 A3 WO2008070358 A3 WO 2008070358A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
tripeptidic
pyrrolopyrazine
pyrrolopyrimidine
pyrrolopyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/083034
Other languages
English (en)
Other versions
WO2008070358A2 (fr
Inventor
David Alan Campbell
Michael E Hepperle
David T Winn
Juan Manuel Betancort
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phenomix Corp
Original Assignee
Phenomix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenomix Corp filed Critical Phenomix Corp
Publication of WO2008070358A2 publication Critical patent/WO2008070358A2/fr
Publication of WO2008070358A3 publication Critical patent/WO2008070358A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux composés qui miment des peptides avec une proline pénultième C-terminale, de tels composés étant utiles en tant qu'inhibiteurs de protéase, notamment en tant qu'inhibiteurs de sérine protéases, et plus particulièrement en tant qu'inhibiteurs de la sérine protéase NS3 du virus de l'hépatite C. Les composés trouvent une utilité en tant qu'agents antiviraux destinés à l'hépatite C. L'invention propose en outre des procédés d'utilisation de tels inhibiteurs, seuls ou en combinaison avec d'autres agents thérapeutiques, pour traiter une infection par l'hépatite C chez un sujet en besoin d'un tel traitement.
PCT/US2007/083034 2006-11-16 2007-10-30 Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci Ceased WO2008070358A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85943306P 2006-11-16 2006-11-16
US60/859,433 2006-11-16
US88459207P 2007-01-11 2007-01-11
US60/884,592 2007-01-11

Publications (2)

Publication Number Publication Date
WO2008070358A2 WO2008070358A2 (fr) 2008-06-12
WO2008070358A3 true WO2008070358A3 (fr) 2008-11-06

Family

ID=39492946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083034 Ceased WO2008070358A2 (fr) 2006-11-16 2007-10-30 Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci

Country Status (1)

Country Link
WO (1) WO2008070358A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159245B (zh) * 2008-09-17 2013-07-24 贝林格尔.英格海姆国际有限公司 Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
NZ598465A (en) * 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012176715A1 (fr) * 2011-06-21 2012-12-27 三菱瓦斯化学株式会社 Amide d'acide 1-amino-2-vinyl cyclopropane carboxylique, sel de celui-ci et son procédé de fabrication
MX360452B (es) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (fr) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
EP2914613B1 (fr) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
CN103408559B (zh) * 2013-08-08 2016-06-29 南京大学 一种喜树碱及其衍生物的快速合成方法

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060926A2 (fr) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2003064416A1 (fr) * 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides heterocycliques utiles en tant qu'inhibiteurs de l'hepatite c
WO2003099274A1 (fr) * 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2004101605A1 (fr) * 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Composes d'inhibition de l'hepatite c
WO2004103996A1 (fr) * 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Composes inhibiteurs de l'hepatite c
WO2005051410A1 (fr) * 2003-11-20 2005-06-09 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006020276A2 (fr) * 2004-07-16 2006-02-23 Gilead Sciences, Inc. Composés antiviraux
WO2006086381A2 (fr) * 2005-02-08 2006-08-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006122188A2 (fr) * 2005-05-10 2006-11-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2007008657A2 (fr) * 2005-07-11 2007-01-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2007014919A1 (fr) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
WO2007015824A2 (fr) * 2005-07-25 2007-02-08 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l’hépatite c
WO2007146695A1 (fr) * 2006-06-06 2007-12-21 Enanta Pharmaceuticals, Inc. Inhibiteurs oximyle acycliques de protéase de l'hépatite c
WO2008005511A2 (fr) * 2006-07-05 2008-01-10 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
WO2008008776A2 (fr) * 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2008021956A2 (fr) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Inhibiteurs d'acylamino-hétéroaryle de la protéase du virus de l'hépatite c

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060926A2 (fr) * 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2003064416A1 (fr) * 2002-02-01 2003-08-07 Boehringer Ingelheim International Gmbh Tripeptides heterocycliques utiles en tant qu'inhibiteurs de l'hepatite c
WO2003099274A1 (fr) * 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2004101605A1 (fr) * 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Composes d'inhibition de l'hepatite c
WO2004103996A1 (fr) * 2003-05-21 2004-12-02 Boehringer Ingelheim International Gmbh Composes inhibiteurs de l'hepatite c
WO2005051410A1 (fr) * 2003-11-20 2005-06-09 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006020276A2 (fr) * 2004-07-16 2006-02-23 Gilead Sciences, Inc. Composés antiviraux
WO2006086381A2 (fr) * 2005-02-08 2006-08-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2006122188A2 (fr) * 2005-05-10 2006-11-16 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2007008657A2 (fr) * 2005-07-11 2007-01-18 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
WO2007015824A2 (fr) * 2005-07-25 2007-02-08 Intermune, Inc. Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l’hépatite c
WO2007014919A1 (fr) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
WO2007146695A1 (fr) * 2006-06-06 2007-12-21 Enanta Pharmaceuticals, Inc. Inhibiteurs oximyle acycliques de protéase de l'hépatite c
WO2008005511A2 (fr) * 2006-07-05 2008-01-10 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
WO2008008776A2 (fr) * 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
WO2008021956A2 (fr) * 2006-08-11 2008-02-21 Enanta Pharmaceuticals, Inc. Inhibiteurs d'acylamino-hétéroaryle de la protéase du virus de l'hépatite c

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102159245B (zh) * 2008-09-17 2013-07-24 贝林格尔.英格海姆国际有限公司 Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合

Also Published As

Publication number Publication date
WO2008070358A2 (fr) 2008-06-12

Similar Documents

Publication Publication Date Title
WO2008070358A3 (fr) Inhibiteurs de la sérine protéase de l'hépatite c et utilisations de ceux-ci
WO2007016476A3 (fr) Inhibiteurs de la sérine protéase de l'hépatite c et emploi desdits inhibiteurs
IL176848A0 (en) Hcv ns-3 serine protease inhibitors
TW200730533A (en) Inhibitors of serine proteases
PL373399A1 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
IL188618A0 (en) Hcv ns3 protease inhibitors
ATE512971T1 (de) Peptidanaloga als hepatitis c-hemmer
IL177544A0 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2004101602A3 (fr) Analogues de peptides inhibiteurs de l'hepatite c
NZ703416A (en) Macrocyclic proline derived hcv serine protease inhibitors
WO2001074768A3 (fr) Inhibiteurs de serine proteases, notamment de la protease ns3 du virus de l'hepatite c
EA200900969A1 (ru) Макроциклические ингибиторы протеазы гепатита с
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
WO2007022459A3 (fr) Procedes et intermediaires
WO2006086381A3 (fr) Inhibiteurs du virus de l'hepatite c
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
EP1910378A4 (fr) Analogues de peptides inhibiteurs de l'hepatite c
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
ZA200703484B (en) HCV NS3-NS4A protease inhibition
WO2008057995A3 (fr) Inhibiteurs de protéase de vhc
ZA200709987B (en) Combination of HCV protease inhibitors with a surfactant
ATE469914T1 (de) Peptide als hemmer der serinprotease des hepatitis c virus
MX2009009174A (es) Inhibidores de serina-proteasas para el tratamiento de infecciones por el virus de hepatitis c.
AU2003277891A1 (en) Hcv ns-3 serine protease inhibitors
WO2006088624A3 (fr) Compositions stabilisees contenant des peptides natriuretiques

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871294

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07871294

Country of ref document: EP

Kind code of ref document: A2